Real-World Data of Tigecycline-Associated Drug-Induced Liver Injury Among Patients in China: A 3-year Retrospective Study as Assessed by the Updated RUCAM.

Shi, Xiaoping; Zuo, Chengchun; Yu, Lingling; Lao, Donghui; Li, Xiaoyu; Xu, Qing; Lv, Qianzhou

Shi, Xiaoping; Zuo, Chengchun; Yu, Lingling; Lao, Donghui; Li, Xiaoyu; Xu, Qing; Lv, Qianzhou.

Afiliação

Shi X; Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
Zuo C; Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
Yu L; Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Lao D; Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
Li X; Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
Xu Q; Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
Lv Q; Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.

Front Pharmacol ; 12: 761167, 2021.

Article em En | MEDLINE | ID: mdl-34795591

Palavras-chave

RUCAM; causality assessment; hepatotoxicity; liver injury; roussel uclaf causality assessment method; tigecycline

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google